Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease

Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease

Show other versions (1)

<h4>Aims</h4> Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system...

Full description

Bibliographic Details
Main Authors: Sebastian Cremer, Lisa Pilgram, Alexander Berkowitsch, Melanie Stecher, Siegbert Rieg, Mariana Shumliakivska, Denisa Bojkova, Julian Uwe Gabriel Wagner, Galip Servet Aslan, Christoph Spinner, Guillermo Luxán, Frank Hanses, Sebastian Dolff, Christiane Piepel, Clemens Ruppert, Andreas Guenther, Maria Madeleine Rüthrich, Jörg Janne Vehreschild, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Arne Hansen, Thomas Eschenhagen, Jindrich Cinatl, Sandra Ciesek, Stefanie Dimmeler, Stefan Borgmann, Andreas Zeiher, on behalf of the LEOSS study group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530317/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530317/?tool=EBI

Similar Items